EMA To Publish All COVID-19 Clinical Data
Move Welcomed By Transparency Advocates
Executive Summary
The European Medicines Agency says the unprecedented public interest in treatments and vaccines being developed for COVID-19 has highlighted the need to provide access to more information than usual.
You may also be interested in...
EMA To Focus On Filings For Novel Drugs Under Restart Of Trial Transparency Policy
The European Medicines Agency is working on restarting its landmark policy on publishing clinical trial data, with the first phase expected to start this year.
Rasi To Ombudsman: No Risk Of Bias In EMA’s COVID-19 Drug Evaluations
European Medicines Agency chief Guido Rasi has responded to questions by the European Ombudsman about its COVID-19 Pandemic Task Force.
COVID-19: Mystery Company Eyes EU Approval For Dexamethasone Taw
The European Medicines Agency has started reviewing under its fast-track pathway an application to market Dexamethasone Taw as a treatment for hospitalized patients with COVID-19.